pyrazinamide has been researched along with Communicable Diseases, Emerging in 1 studies
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.
Communicable Diseases, Emerging: Infectious diseases that are novel in their outbreak ranges (geographic and host) or transmission mode.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calver, AD | 1 |
| Falmer, AA | 1 |
| Murray, M | 1 |
| Strauss, OJ | 1 |
| Streicher, EM | 1 |
| Hanekom, M | 1 |
| Liversage, T | 1 |
| Masibi, M | 1 |
| van Helden, PD | 1 |
| Warren, RM | 1 |
| Victor, TC | 1 |
1 other study available for pyrazinamide and Communicable Diseases, Emerging
| Article | Year |
|---|---|
Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa.
Topics: Adult; Antitubercular Agents; Communicable Diseases, Emerging; Contact Tracing; Directly Observed Th | 2010 |